Evaluation of the biological activity of a new chemical compound as a chemical therapeutic medicine for ovarian cancer

Postgraduate Thesis uoadl:2883740 179 Read counter

Unit:
Κατεύθυνση Κλινική Χημεία
Library of the School of Science
Deposit date:
2019-10-25
Year:
2019
Author:
Kakoulli Styliani
Supervisors info:
Αριστείδης Γ. Ηλιόπουλος, Καθηγητής, Διευθυντής Εργαστηρίου Βιολογίας, Ιατρική σχολή, ΕΚΠΑ (Εθνικον και καποδιστριακον πανεπιστημιον αθηνων)
Original Title:
ΑΠΟΤΙΜΗΣΗ ΤΗΣ ΒΙΟΛΟΓΙΚΗΣ ΔΡΑΣΗΣ ΜΙΑΣ ΝΕΑΣ ΧΗΜΙΚΗΣ ΕΝΩΣΗΣ ΩΣ ΧΗΜΙΚΟΘΕΡΑΠΕΥΤΙΚΟ ΦΑΡΜΑΚΟ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ ΤΩΝ ΩΟΘΗΚΩΝ
Languages:
Greek
Translated title:
Evaluation of the biological activity of a new chemical compound as a chemical therapeutic medicine for ovarian cancer
Summary:
Ovarian cancer is one of the few cancers which is diagnosed at an advanced stage. It is one of the most common gynaecological death’s cause. The treatment of this cancer requires further research and is one of the greatest interest of the scientific community. Specifically, epithelial ovarian cancer is divided into other subtypes which complicate this disease further.
In this thesis, a literature review is made on ovarian cancer, the categorized symptoms, the main diagnostic and treatment modalities.
The main purpose of this thesis is to study the biological effect of a new compound, «compound 127», to qualify as a chemotherapeutic drug for this cancer. This study focused on the cytotoxicity of this compound and the mechanism which affect the DNA. All experiments were performed in the Biology Laboratory in Medical School of the National and Kapodistrian University of Athens with two ovarian cancer cell lines: the A2780 with sensitivity to cisplatin and the A2780CP with resistivity to cisplatin. Various techniques were used such as cell culture, MTT assay, cell cycle, colony formation, Western blot and immunofluorescence. All studies were always compared to the main chemotherapeutic drug, the cisplatin.
In conclusion, the «compound 127» appears to have chemotherapeutic activity at a lower concentration than cisplatin because it induces cell death more rapidly, it may take longer to act than cisplatin by killing more cancer cells. It also concentrates at a different phase in the cell cycle than cisplatin and this means that it acts by a different mechanism than it.
Main subject category:
Science
Keywords:
ovary, chemotherapy, cytotoxicity, sensitivity, durability
Index:
No
Number of index pages:
0
Contains images:
Yes
Number of references:
123
Number of pages:
75
Διπλωματικη εργασία- Στυλιανής Κακουλλής-pdf.pdf (2 MB) Open in new window